[go: up one dir, main page]

IN2012DN05888A - - Google Patents

Info

Publication number
IN2012DN05888A
IN2012DN05888A IN5888DEN2012A IN2012DN05888A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A IN 5888DEN2012 A IN5888DEN2012 A IN 5888DEN2012A IN 2012DN05888 A IN2012DN05888 A IN 2012DN05888A
Authority
IN
India
Prior art keywords
pro
emulsion formulations
taxane
kits
making
Prior art date
Application number
Inventor
Kiichiro Nabeta
Original Assignee
Teikoku Pharma Usa Inc
Techno Guard Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc, Techno Guard Co Ltd filed Critical Teikoku Pharma Usa Inc
Publication of IN2012DN05888A publication Critical patent/IN2012DN05888A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane  oil  surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations  as well as kits that include the pro-emulsion formulations.
IN5888DEN2012 2010-02-19 2011-02-18 IN2012DN05888A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30631510P 2010-02-19 2010-02-19
PCT/US2011/025418 WO2011103413A2 (en) 2010-02-19 2011-02-18 Taxane pro-emulsion formulations and methods making and using the same

Publications (1)

Publication Number Publication Date
IN2012DN05888A true IN2012DN05888A (en) 2015-09-18

Family

ID=44477026

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5888DEN2012 IN2012DN05888A (en) 2010-02-19 2011-02-18

Country Status (9)

Country Link
US (2) US8569357B2 (en)
EP (1) EP2536407A4 (en)
JP (1) JP2013520435A (en)
KR (1) KR20120126072A (en)
CN (1) CN102762202A (en)
AU (1) AU2011217951B2 (en)
IN (1) IN2012DN05888A (en)
TW (1) TWI438009B (en)
WO (1) WO2011103413A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013268725B2 (en) * 2012-05-31 2017-02-16 Asahi Kasei Pharma Corporation Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
JO3685B1 (en) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
DE4208527A1 (en) * 1992-03-17 1993-09-23 Max Planck Gesellschaft LIPOSOMES WITH NEGATIVE EXCESS CHARGE
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
FR2698543B1 (en) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
DK0693924T4 (en) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Process for (in vivo) delivery of biological materials and compositions suitable therefor
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4447770C2 (en) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Process for the production of liposomally encapsulated taxol
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
KR100330373B1 (en) * 1996-05-28 2002-11-07 주식회사한국신약 Pharmaceutical composition for injection containing taxol
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
KR100509130B1 (en) * 1997-07-29 2005-08-18 파마시아 앤드 업존 캄파니 엘엘씨 Self-Emulsifying Formulation for Lipophilic Compounds
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6281175B1 (en) * 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
DE69917609T2 (en) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao MEDICINES AND ITS USE
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2332545A1 (en) * 1998-05-20 1999-11-25 The Liposome Company, Inc. Novel particulate formulations
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
MXPA01011981A (en) * 1999-05-24 2003-09-04 Sonus Pharma Inc Emulsion vehicle for poorly soluble drugs.
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CN100376291C (en) * 1999-05-27 2008-03-26 阿库斯菲尔公司 Porous drug matrices and methods of manufacture thereof
TW422706B (en) * 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
JP3448006B2 (en) * 2000-03-29 2003-09-16 独立行政法人食品総合研究所 Functional emulsion
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10036871A1 (en) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersions for the formulation of poorly or poorly soluble active ingredients
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
WO2003057128A2 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
DE60309731T2 (en) * 2002-08-21 2007-06-28 Pharmacia Corp. INJECTABLE PHARMACEUTICAL SUSPENSION IN A TWO-CHAMBERED PHIO
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
AR054215A1 (en) * 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
WO2010018596A2 (en) * 2008-07-23 2010-02-18 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
CN101428002A (en) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 Paclitaxel freeze drying microemulsion for injection and method of producing the same

Also Published As

Publication number Publication date
KR20120126072A (en) 2012-11-20
US20140088181A1 (en) 2014-03-27
WO2011103413A2 (en) 2011-08-25
AU2011217951A1 (en) 2012-07-19
CN102762202A (en) 2012-10-31
TWI438009B (en) 2014-05-21
US20110207803A1 (en) 2011-08-25
EP2536407A4 (en) 2013-08-14
JP2013520435A (en) 2013-06-06
US8569357B2 (en) 2013-10-29
WO2011103413A3 (en) 2012-01-12
EP2536407A2 (en) 2012-12-26
TW201141538A (en) 2011-12-01
AU2011217951B2 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
WO2012077120A3 (en) Natural formulations
WO2013123114A3 (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2012051210A3 (en) Mesenchymal stem cells and related therapies
GEP201706733B (en) Anti-il-23 antibodies
WO2012099930A3 (en) Flavonol compositions
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
ZA201401782B (en) Chromobacterium formulations,compositions,metabolites and their uses
MY170720A (en) Antibody formulations
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
EP3068500A4 (en) Fertilizer compositions and methods of making and using the same
MY167224A (en) Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
IN2012DN03404A (en)
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
CA2875305C (en) Fbxo3 inhibitors
WO2012088222A3 (en) Methods and compositions for producing active vitamin k-dependent proteins
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
EP2640953A4 (en) Propellant compositions and methods of making and using the same
IN2012DN05888A (en)
MX2013000539A (en) New formulations of 14 - epi -analogues of vitamin d.
WO2012051126A3 (en) Anti-inflammatory macrolides
WO2014003950A3 (en) Selenium containing nucleosides as nutritional supplements
WO2012139074A3 (en) Migrastatins and uses thereof
WO2012004073A3 (en) Use of beta-isophorone as solvent